GlassScriptPhysician profile
Karthik V Garapati
NPI 1659717445
$6,250.75
in general payments reported to CMS, 2019-2025
31 companies · $1,635 in 2025
The $1,635 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $198 · 2020: $108 · 2021: $402 · 2022: $726 · 2023: $1,672 · 2024: $1,509 · 2025: $1,635.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,802 · Education: $14.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,801.95 |
| Education | $14.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,551.90 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $526.73 | 2020-2025 | Xifaxan, Trulance |
| Celgene Corporation | $501.82 | 2022-2024 | Zeposia |
| Pfizer INC. | $451.34 | 2023-2025 | |
| Janssen Biotech, INC. | $306.20 | 2023-2025 | Stelara, Tremfya |
| Qol Medical, LLC | $195.29 | 2021-2025 | Sucraid |
| Aimmune Therapeutics, INC. | $167.35 | 2025 | Zenpep |
| Genzyme Corporation | $145.53 | 2022-2025 | |
| Intuitive Surgical, INC. | $145.41 | 2023 | Da Vinci Surgical System |
| Boston Scientific Corporation | $132.35 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $130.18 | 2022-2023 | Zeposia |
| Madrigal Pharmaceuticals | $123.51 | 2024-2025 | Rezdiffra, Resmetirom |
| Shire North American Group INC | $122.60 | 2019 | |
| Phathom Pharmaceuticals, INC. | $96.43 | 2024-2025 | Voquezna |
| Ardelyx, INC. | $95.35 | 2022-2025 | Ibsrela |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Scientific Affairs, LLC | $74.90 | 2019 | |
| Gilead Sciences, INC. | $69.32 | 2023-2025 | |
| Lilly USA, LLC | $54.26 | 2023-2024 | Omvoh |
| Ipsen Biopharmaceuticals, INC | $53.75 | 2025 | Iqirvo |
| Celltrion USA INC. | $49.35 | 2024-2025 | Vegzelma |
| Organon LLC | $48.50 | 2023-2024 | Renflexis, Hadlima |
| Redhill Biopharma INC. | $44.69 | 2021-2023 | Talicia |
| Intercept Pharmaceuticals, INC. | $34.53 | 2022-2023 | Ocaliva |
| Shionogi INC | $23.99 | 2020 | |
| Ironwood Pharmaceuticals, INC | $21.09 | 2024 | |
| Shield Therapeutics INC | $20.63 | 2022 | |
| Novo Nordisk INC | $20.62 | 2025 | Wegovy |
| Nestle Healthcare Nutrition INC. | $15.25 | 2021 | |
| Ferring Pharmaceuticals INC. | $14.53 | 2023 | Rebyota |
| Braintree Laboratories, INC. | $13.35 | 2023 | Sutab, Suflave |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$26,285.56 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Karthik Garapati listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.